Repligen | RGEN - Debt


Repligen reported $690.94M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Agilent USD 3.35B 0 Dec/2025
Align Technology USD 116.04M 1.6M Mar/2026
Bio Techne USD 200M 60M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Bruker USD 1.67B 371.6M Mar/2026
Charles River Laboratories USD 3.06B 485.84M Mar/2026
Danaher USD 26.56B 8.07B Jun/2026
Dentsply International USD 2.33B 137M Mar/2026
General Electric Aerospace USD 19.16B 1.12B Jun/2026
Henry Schein USD 3.75B 313M Mar/2026
Illumina USD 2.54B 9M Mar/2026
IQVIA Holdings USD 16.24B 408M Jun/2026
Mettler Toledo International USD 2.23B 76.47M Mar/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
OraSure Technologies USD 782K 465K Jun/2024
Pacific Biosciences Of California USD 892.24M 653K Dec/2023
Pfizer USD 63.73B 231M Mar/2026
Repligen USD 690.94M 144.36M Jun/2026
Revvity USD 3.35B 48.03M Mar/2026
Standard Biotools USD 29.49M 2.1M Mar/2026
Thermo Fisher Scientific USD 43.16B 3.78B Mar/2026
Waters USD 5.57B 4.08B Mar/2026
West Pharmaceutical Services USD 202.8M 0 Mar/2026